SCHEMBL6740845

SCHEMBL6740845

CCN(CC)CCc1ccc2cnn(C(C)C)c2c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 2/20 0.40
HDAC8 Q9BY41 1/20 0.39
KMO O15229 1/20 0.37
SIGMAR1 Q99720 2/20 0.36
CYP51A1 Q16850 2/20 0.34
HTR1A P08908 1/20 0.34
HTR1D P28221 1/20 0.34
HTR1B P28222 1/20 0.34
HTR2A P28223 1/20 0.34
HTR1E P28566 1/20 0.34
HTR7 P34969 1/20 0.34
HTR2B P41595 1/20 0.34
HTR5A P47898 1/20 0.34
PTGER3 P43115 1/20 0.34
PDE1A P54750 2/20 0.33
PDE1B Q01064 2/20 0.33
PDE1C Q14123 2/20 0.33
BIRC5 O15392 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6743454 0.86 HRH3 (0.39) HRH3HDAC8KMOSIGMAR1HTR1A
SCHEMBL12327554 0.81 HDAC8 (0.53) HDAC8KMOHTR1AHTR1DHTR2A
SCHEMBL6746000 0.78 HRH3 (0.40) HRH3KMOSIGMAR1HTR1AHTR1D
SCHEMBL30174486 0.77 KMO (0.45) HDAC8KMOHTR1AHTR1DHTR2A
SCHEMBL20942425 0.77 HDAC8 (0.43) HDAC8KMOHTR1AHTR1DHTR2A
SCHEMBL15687398 0.77 KMO (0.45) HDAC8KMOHTR1AHTR1DHTR2A
SCHEMBL6740857 0.75 HRH3 (0.42) HRH3SIGMAR1HTR1AHTR1DHTR1B
SCHEMBL19966783 0.74 KMO (0.40) HDAC8KMOHTR1AHTR1DHTR2A
SCHEMBL6746545 0.74 SIGMAR1 (0.48) HRH3SIGMAR1HTR7CYP2D6
SCHEMBL6740869 0.73 KMO (0.38) HDAC8KMOHTR1AHTR1DHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040167158-A1 Heterocyclic compounds for the treatment of migraine NPS ALLELIX BIOPHARMACEUTICALS, INC. (CA) 2004-08-26 US disclosed
US-6716837-B1 INDOLE AND INDAZOLE COMPOUNDS NPS ALLELIX BIOPHARMACEUTICALS, INC. (CA) 2004-04-06 US disclosed
EP-1196380-A2 INDOLES AND INDAZOLES FOR THE TREATMENT OF MIGRAINE NPS Allelix Corp. (CA) 2002-04-17 EP disclosed
WO-2001005758-A2 INDOLES AND INDAZOLES FOR THE TREATMENT OF MIGRAINE NPS ALLELIX CORP. (CA) 2001-01-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040167158-A1 Heterocyclic compounds for the treatment of migraine SCN7A, CNR2, HTR7 HRH3 21/4885HDAC8 428/4885KMO 453/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.